Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.88 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.88 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.67 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.62 |
| ▸ | HTR3B | O95264 | 1/20 | 0.62 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664269 | 0.94 | CHRNB2 (1.00) | CHRNB2CHRNA4ADRB1 | |
| SCHEMBL6352766 | 0.90 | CHRNB2 (1.00) | CHRNB2CHRNA4ADRB1 | |
| SCHEMBL6348961 | 0.90 | CHRNB2 (0.74) | CHRNB2CHRNA4ADRB1TGFBR1HTR3E | |
| Trifluoroacetic Acid SCHEMBL26600964 | 0.87 | CHRNB2 (0.68) | CHRNB2CHRNA4ADRB1TGFBR1HTR3E | |
| Trifluoroacetic Acid SCHEMBL30618979 | 0.87 | CHRNB2 (0.68) | CHRNB2CHRNA4ADRB1TGFBR1HTR3E | |
| SCHEMBL7167940 | 0.83 | CHRNB2 (0.77) | CHRNB2CHRNA4 | |
| SCHEMBL6358253 | 0.83 | CHRNB2 (0.63) | CHRNB2CHRNA4ADRB1TGFBR1ACVR1 | |
| SCHEMBL3453466 | 0.83 | CHRNB2 (0.66) | CHRNB2CHRNA4 | |
| SCHEMBL12205345 | 0.82 | CHRNB2 (0.75) | CHRNB2CHRNA4 | |
| SCHEMBL6349656 | 0.81 | CHRNB2 (0.83) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491532-B1 | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetyloholine receptors | NEUROSEARCH AS (DK) | 2010-12-15 | — | — | EP | claimed |
| US-6897219-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2005-05-24 | — | — | US | claimed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | claimed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-1491532-B1 | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetyloholine receptors | NEUROSEARCH AS (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2010-10-21 | — | — | US | disclosed |
| US-7307087-B2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH A/S (DK) | 2007-12-11 | — | — | US | disclosed |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2007-11-15 | — | — | US | disclosed |
| EP-1757600-A2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NeuroSearch A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| EP-1027336-B1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | disclosed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | disclosed |
| CN-1131211-C | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH AS (DK) | 2003-12-17 | — | — | CN | disclosed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
| CN-1277604-A | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH AS (DK) | 2000-12-20 | — | — | CN | disclosed |
| EP-1027336-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021834-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | TAAR5, CHRNA5, CHRNA4 | CHRNB2 15/4885CHRNA4 3/4885ADRB1 135/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | CHRNB2 4553/4885CHRNA4 4754/4885ADRB1 1308/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | CHRNB2 15/4885CHRNA4 3/4885ADRB1 135/4885 |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | OGFR, CBR3, OGFRL1 | CHRNB2 700/4885CHRNA4 1019/4885ADRB1 179/4885 |
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | CHRNA10, CHRNA2, CHRNA7 | CHRNB2 14/4885CHRNA4 5/4885ADRB1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.